JP2013023450A - ジペプチジルペプチダーゼiv阻害剤 - Google Patents
ジペプチジルペプチダーゼiv阻害剤 Download PDFInfo
- Publication number
- JP2013023450A JP2013023450A JP2011157218A JP2011157218A JP2013023450A JP 2013023450 A JP2013023450 A JP 2013023450A JP 2011157218 A JP2011157218 A JP 2011157218A JP 2011157218 A JP2011157218 A JP 2011157218A JP 2013023450 A JP2013023450 A JP 2013023450A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- dipeptidyl peptidase
- inhibitor
- parts
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 title abstract description 26
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 76
- 244000000231 Sesamum indicum Species 0.000 claims abstract description 28
- 235000003434 Sesamum indicum Nutrition 0.000 claims abstract description 28
- 244000062730 Melissa officinalis Species 0.000 claims abstract description 24
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims abstract description 23
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims abstract description 23
- 235000010654 Melissa officinalis Nutrition 0.000 claims abstract description 23
- 244000134540 Polymnia sonchifolia Species 0.000 claims abstract description 22
- 235000003406 Polymnia sonchifolia Nutrition 0.000 claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 22
- 239000009429 Ginkgo biloba extract Substances 0.000 claims abstract description 17
- 229940068052 ginkgo biloba extract Drugs 0.000 claims abstract description 17
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims abstract description 17
- 229930014626 natural product Natural products 0.000 claims abstract description 8
- 240000006365 Vitis vinifera Species 0.000 claims description 10
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 18
- 239000000470 constituent Substances 0.000 abstract description 8
- 241000328973 Tilia miqueliana Species 0.000 abstract 1
- 235000009392 Vitis Nutrition 0.000 abstract 1
- 241000219095 Vitis Species 0.000 abstract 1
- 238000000605 extraction Methods 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000002994 raw material Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229940038487 grape extract Drugs 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 244000194101 Ginkgo biloba Species 0.000 description 7
- 235000008100 Ginkgo biloba Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 239000000859 incretin Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 235000011201 Ginkgo Nutrition 0.000 description 5
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 240000007313 Tilia cordata Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000005238 degreasing Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- -1 aliphatic alcohols Chemical class 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000776115 Ampelopsis glandulosa var. brevipedunculata Species 0.000 description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 206010056438 Growth hormone deficiency Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 208000008765 Sciatica Diseases 0.000 description 2
- 241000748489 Smallanthus Species 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 235000015450 Tilia cordata Nutrition 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- OTWVFHZMWFGHSJ-UHFFFAOYSA-N 1-fluoropyrrolidine Chemical compound FN1CCCC1 OTWVFHZMWFGHSJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 241000207960 Pedaliaceae Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000001417 melissa officinalis l. Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
【解決手段】本発明のジペプチジルペプチダーゼIV阻害剤の有効成分として、ノブドウ抽出物、ゴマペプチド、レモンバーム抽出物、イチョウ抽出物、ヤーコン抽出物及びボダイジュ抽出物からなる群より選択される1種又は2種以上の天然物由来成分を含有させる。
【選択図】なし
Description
本実施形態のジペプチジルペプチダーゼIV阻害剤は、ノブドウ抽出物、ゴマペプチド、レモンバーム抽出物、イチョウ抽出物、ヤーコン抽出物及びボダイジュ抽出物からなる群より選択される1種又は2種以上の天然物由来成分を有効成分として含有するものである。
本実施形態において、ノブドウ抽出物、レモンバーム抽出物、イチョウ抽出物、ヤーコン抽出物及びボダイジュ抽出物を製造するために使用する抽出原料は、ノブドウ(学名:Ampelopsis brevipedunculata Trautv.)、レモンバーム(学名:Melissa officinalis L.)、イチョウ(学名:Ginkgo biloba L.)、ヤーコン(学名:Smallanthus sonchifolia)、及びボダイジュ(学名:Tilia cordata)である。
本実施形態におけるゴマペプチドは、ゴマ(学名:Sesamum indicum)を抽出して得られるゴマタンパク質をプロテアーゼ等により酵素処理して得られるものである。
以上のようにして得られるノブドウ抽出物、ゴマペプチド、レモンバーム抽出物、イチョウ抽出物、ヤーコン抽出物及びボダイジュ抽出物は、優れたジペプチジルペプチダーゼIV阻害作用を有しているため、ジペプチジルペプチダーゼIV阻害剤の有効成分として用いることができる。本実施形態のジペプチジルペプチダーゼIV阻害剤は、医薬品、医薬部外品、化粧品等の幅広い用途に使用することができる。
上記各天然物由来成分(試料1〜6)について、以下のようにしてジペプチジルペプチダーゼIV(DPPIV)阻害作用を試験した。
式中、Aは「試料無添加、酵素添加での波長415nmにおける吸光度」を表し、Bは「試料無添加、酵素無添加での波長415nmにおける吸光度」を表し、Cは「被験試料添加、酵素添加での波長415nmにおける吸光度」を表し、Dは「被験試料添加、酵素無添加での波長415nmにおける吸光度」を表す。
結果を表2に示す。
Claims (1)
- ノブドウ抽出物、ゴマペプチド、レモンバーム抽出物、イチョウ抽出物、ヤーコン抽出物及びボダイジュ抽出物からなる群より選択される1種又は2種以上の天然物由来成分を有効成分として含有するジペプチジルペプチダーゼIV阻害剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011157218A JP5854674B2 (ja) | 2011-07-15 | 2011-07-15 | ジペプチジルペプチダーゼiv阻害剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011157218A JP5854674B2 (ja) | 2011-07-15 | 2011-07-15 | ジペプチジルペプチダーゼiv阻害剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013023450A true JP2013023450A (ja) | 2013-02-04 |
JP5854674B2 JP5854674B2 (ja) | 2016-02-09 |
Family
ID=47782184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011157218A Active JP5854674B2 (ja) | 2011-07-15 | 2011-07-15 | ジペプチジルペプチダーゼiv阻害剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5854674B2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018030794A (ja) * | 2016-08-23 | 2018-03-01 | 株式会社真誠プランニング | 脂肪細胞分化促進剤 |
JP2018111735A (ja) * | 2018-04-24 | 2018-07-19 | 丸善製薬株式会社 | Tie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物 |
JP2022125300A (ja) * | 2017-01-31 | 2022-08-26 | 株式会社東洋新薬 | オーラルケア用経口組成物 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003206233A (ja) * | 2002-01-09 | 2003-07-22 | Ryusendo:Kk | C型慢性肝炎患者用保健食品 |
JP2005015364A (ja) * | 2003-06-25 | 2005-01-20 | Maruzen Pharmaceut Co Ltd | 抗酸化組成物、皮膚老化防止用組成物、抗炎症組成物及び脂質代謝改善用組成物 |
JP2005082568A (ja) * | 2003-09-11 | 2005-03-31 | Maruzen Pharmaceut Co Ltd | グルコシルトランスフェラーゼ阻害剤、プラーク形成抑制剤、抗菌剤、口腔用剤およびう触予防用飲食物 |
JP2005306750A (ja) * | 2004-04-19 | 2005-11-04 | Maruzen Pharmaceut Co Ltd | 飲酒後の呼気のアルコール濃度低減剤及び飲食物、並びに飲酒後の呼気のアルコール濃度低減方法 |
JP2005306793A (ja) * | 2004-04-22 | 2005-11-04 | Maruzen Pharmaceut Co Ltd | ノブドウ抽出物組成物、ノブドウ抽出物含有飲食物、及びノブドウ抽出物の呈味改善方法 |
JP2007277163A (ja) * | 2006-04-06 | 2007-10-25 | Uha Mikakuto Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
JP2008501647A (ja) * | 2004-06-04 | 2008-01-24 | 澳美▲製▼▲薬▼▲ツァン▼有限公司 | ノブドウ属植物およびその抽出物の薬品および保健品調製への応用 |
JP2010006748A (ja) * | 2008-06-27 | 2010-01-14 | Kirin Holdings Co Ltd | ジペプチジルペプチダーゼiv阻害物質 |
JP2010013423A (ja) * | 2008-07-07 | 2010-01-21 | Lion Corp | ジペプチジルペプチダーゼ−iv阻害剤 |
JP2010095529A (ja) * | 2009-12-22 | 2010-04-30 | Maruzen Pharmaceut Co Ltd | 脂質代謝改善用組成物 |
JP2010120946A (ja) * | 2009-12-22 | 2010-06-03 | Maruzen Pharmaceut Co Ltd | 抗炎症組成物 |
WO2011016220A1 (ja) * | 2009-08-03 | 2011-02-10 | 株式会社カネカ | ジペプチジルペプチダーゼ-4阻害剤 |
JP2012082172A (ja) * | 2010-10-13 | 2012-04-26 | Univ Of Tokushima | チョウセンゴミシ水抽出エキスを有効成分として含有するジペプチジルペプチダーゼiv阻害剤 |
-
2011
- 2011-07-15 JP JP2011157218A patent/JP5854674B2/ja active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003206233A (ja) * | 2002-01-09 | 2003-07-22 | Ryusendo:Kk | C型慢性肝炎患者用保健食品 |
JP2005015364A (ja) * | 2003-06-25 | 2005-01-20 | Maruzen Pharmaceut Co Ltd | 抗酸化組成物、皮膚老化防止用組成物、抗炎症組成物及び脂質代謝改善用組成物 |
JP2005082568A (ja) * | 2003-09-11 | 2005-03-31 | Maruzen Pharmaceut Co Ltd | グルコシルトランスフェラーゼ阻害剤、プラーク形成抑制剤、抗菌剤、口腔用剤およびう触予防用飲食物 |
JP2005306750A (ja) * | 2004-04-19 | 2005-11-04 | Maruzen Pharmaceut Co Ltd | 飲酒後の呼気のアルコール濃度低減剤及び飲食物、並びに飲酒後の呼気のアルコール濃度低減方法 |
JP2005306793A (ja) * | 2004-04-22 | 2005-11-04 | Maruzen Pharmaceut Co Ltd | ノブドウ抽出物組成物、ノブドウ抽出物含有飲食物、及びノブドウ抽出物の呈味改善方法 |
JP2008501647A (ja) * | 2004-06-04 | 2008-01-24 | 澳美▲製▼▲薬▼▲ツァン▼有限公司 | ノブドウ属植物およびその抽出物の薬品および保健品調製への応用 |
JP2007277163A (ja) * | 2006-04-06 | 2007-10-25 | Uha Mikakuto Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
JP2010006748A (ja) * | 2008-06-27 | 2010-01-14 | Kirin Holdings Co Ltd | ジペプチジルペプチダーゼiv阻害物質 |
JP2010013423A (ja) * | 2008-07-07 | 2010-01-21 | Lion Corp | ジペプチジルペプチダーゼ−iv阻害剤 |
WO2011016220A1 (ja) * | 2009-08-03 | 2011-02-10 | 株式会社カネカ | ジペプチジルペプチダーゼ-4阻害剤 |
JP2010095529A (ja) * | 2009-12-22 | 2010-04-30 | Maruzen Pharmaceut Co Ltd | 脂質代謝改善用組成物 |
JP2010120946A (ja) * | 2009-12-22 | 2010-06-03 | Maruzen Pharmaceut Co Ltd | 抗炎症組成物 |
JP2012082172A (ja) * | 2010-10-13 | 2012-04-26 | Univ Of Tokushima | チョウセンゴミシ水抽出エキスを有効成分として含有するジペプチジルペプチダーゼiv阻害剤 |
Non-Patent Citations (2)
Title |
---|
JPN6015017152; Enzyme Protein 1994-1995 48, 51-60 * |
JPN6015034424; 中薬大辞典 第二巻, 19980501, p.1151, 株式会社 小学館 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018030794A (ja) * | 2016-08-23 | 2018-03-01 | 株式会社真誠プランニング | 脂肪細胞分化促進剤 |
JP2022125300A (ja) * | 2017-01-31 | 2022-08-26 | 株式会社東洋新薬 | オーラルケア用経口組成物 |
JP7475718B2 (ja) | 2017-01-31 | 2024-04-30 | 株式会社東洋新薬 | オーラルケア用経口組成物 |
JP2018111735A (ja) * | 2018-04-24 | 2018-07-19 | 丸善製薬株式会社 | Tie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP5854674B2 (ja) | 2016-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5441232B2 (ja) | メイラード反応阻害剤 | |
JP5969738B2 (ja) | 抗糖化作用剤 | |
JP5230152B2 (ja) | プロフィラグリン産生促進剤及びフィラグリン産生促進剤 | |
Chawla et al. | A review of chemistry and biological activities of the genus Aerva--a desert plant | |
KR20110017402A (ko) | 유칼리 추출물의 조제 방법 | |
JP2012121874A (ja) | 抗糖化作用剤 | |
JPWO2014126199A1 (ja) | 酸化タンパク質分解酵素活性増強化剤 | |
JP5854674B2 (ja) | ジペプチジルペプチダーゼiv阻害剤 | |
JP6781549B2 (ja) | Endo180産生促進剤 | |
JP2009084169A (ja) | コラーゲン産生作用を呈するキサントン誘導体及びその製造方法 | |
JP2008081440A (ja) | アロマターゼ活性促進剤 | |
KR102120220B1 (ko) | 천연식물 발효 추출물을 함유하는 복부 비만 감소용 화장료 또는 식품 조성물 | |
JP2011001326A (ja) | エンドセリン−1mRNA発現抑制剤 | |
JP2015086168A (ja) | リパーゼ阻害剤および皮脂コントロール用皮膚化粧料 | |
JP2012067061A (ja) | メイラード反応阻害剤及び老化改善剤 | |
JP5896618B2 (ja) | メラニン産生抑制剤 | |
JP2022078258A (ja) | エンドセリン変換酵素阻害剤 | |
KR20220040421A (ko) | 창포 추출물을 활용한 동물용 세정제 조성물 | |
JP2012025777A (ja) | 血管新生抑制剤及び外用剤 | |
JP2011001328A (ja) | 塩基性線維芽細胞増殖因子mRNA発現上昇抑制剤 | |
JP5992661B2 (ja) | ヒアルロン酸産生促進剤 | |
JP6385533B2 (ja) | リパーゼ阻害剤および皮脂分解抑制用皮膚化粧料 | |
JP2019055924A (ja) | Endo180産生促進剤 | |
JP2010215535A (ja) | メラニン産生抑制剤 | |
JP5970098B2 (ja) | 抗糖化作用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140528 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150623 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151102 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151117 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5854674 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |